Browse drugs

…patient in sitravatinib+tislelizumab arm; 13 (6.8%) patients in docetaxel arm) (figure 1). One patient randomised to sitravatinib+tisleli…

…l lung cancer (ES-SCLC) provides only modest survival benefits. Tislelizumab has been recently approved by the European Commission, but head…

…xel arm. Grade 5 haemoptysis occurred in 3 (1.6%) patients with sitravatinib plus tislelizumab. The study was terminated due to an unfavoura…

…as ‘related,’ ‘most possibly related,’ or ‘possibly related’ to SSGJ-707 or tislelizumab.Abstract 1328 Figure 1Waterfall plots for SSGJ-…

…y alone followed by second-line paclitaxel in both arms.Results Tislelizumab resulted in a gain of 0.543 QALYs (95% CI 0.432 to 0.610) and 0…

… tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BAL0891 monotherapy and combination with paclitaxel.Trial Registration …

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

…T） on imaging 1 week after treatment. All patients will receive tislelizumab (200 mg every 3 weeks) for 6 months. Follow-up will continue un…

…by body surface area). HER2-positive patients will also receive trastuzumab. Primary endpoint: 1-year overall survival. Secondary endpoints…

…experienced severe reactions. The five most reported drugs were nivolumab (92,753; 44.4%), pembrolizumab (62,096; 29.7%), atezolizumab (3…

… Group performance status of 0 or 1. Eligible patients received tislelizumab (200 mg, IV Q3W) or sintilimab (200 mg, IV Q3W) for a lead-in p…